+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers



Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers



European Journal of Clinical Pharmacology 62(1): 83-85




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049000673

Download citation: RISBibTeXText

PMID: 16369813

DOI: 10.1007/s00228-005-0067-x


Related references

Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. Journal of Clinical Pharmacology 44(12): 1368-1378, 2004

Effect of R411, a dual alpha4/beta1-alpha4/beta7 integrin antagonist being developed for asthma, on the activities of the major drug metabolizing enzymes after oral administration in healthy subjects. Clinical Pharmacology & Therapeutics 75(2): P79, 2004

Parallel-synthesis optimization of TR-14035, a dual-active alpha4beta7/alpha4beta1 integrin antagonist Generation of alpha4beta1 selective antagonists. Abstracts of Papers American Chemical Society 218(1-2): MEDI 61, 1999

SAR of TR-14035 An orally active dual alpha4beta7/alpha4beta1 integrin antagonist. Abstracts of Papers American Chemical Society 218(1-2): MEDI 60, 1999

Discovery of TR-14035 An orally active dual alpha4beta7/alpha4beta1 integrin antagonist. Abstracts of Papers American Chemical Society 218(1-2): MEDI 59, 1999

A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence. Journal of Pharmacology and Experimental Therapeutics 306(3): 903-913, 2003

Safety, tolerability, and pharmacokinetics of R411, a dual alpha4/beta1-alpha4/beta7 integrin antagonist, after oral administration of single-ascending doses in healthy male subjects. Journal of Allergy & Clinical Immunology 113(2 Suppl.): S218, 2004

Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharmaceutical Research 23(11): 2646-2656, 2006

Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores. Bioorganic & Medicinal Chemistry Letters 12(20): 2913-2917, 2002

Role of human liver cytochrome P450 2C9 in the metabolism of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Drug Metabolism and Pharmacokinetics 20(2): 127-134, 2005

Mo1706 Inhibitory Effects of an Orally Active Small Molecule Alpha4beta1/ Alpha4beta7 Integrin Antagonist, Trk-170, on Spontaneous Colitis in Hlab27 Transgenic Rats. Gastroenterology 146(5): S-640, 2014

A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats. British Journal of Pharmacology 147(6): 661-670, 2006

Selective modulation of inflammatory responses without immunosuppression with the dual alpha4/beta1-alpha4/beta7 integrin antagonist R411 in vivo. Journal of Allergy & Clinical Immunology 113(2 Suppl.): S208, 2004

Andrographis paniculata: Dissolution investigation and pharmacokinetic studies of four major active diterpenoids after multiple oral dose administration in healthy Thai volunteers. Journal of Ethnopharmacology 194: 513-521, 2016

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clinical Therapeutics 30(11): 2051-2068, 2009